Cediranib
Thyroid Gland Medullary Carcinoma
Vanderbilt-Ingram Cancer CenterSmall moleculePhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 44/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Thyroid Gland Medullary Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Everolimus National Cancer Institute (NCI) | Phase 1 | CCC |
Recombinant Interleukin-12 National Cancer Institute (NCI) | Phase 1 | CC |
Temsirolimus University of Southern California | Phase 1 | CC |
Octreotide Pamoate National Cancer Institute (NCI) | Phase 1 | CC |
ptk787 Mayo Clinic | Phase 1 | CC |
View all 20 →
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →